Changeflow GovPing Pharma & Drug Safety Expression Control Using a Regulatable Intron
Routine Notice Added Final

Expression Control Using a Regulatable Intron

Favicon for changeflow.com USPTO Patent Grants - Biotech (C12N)
Published
Detected
Email

Summary

The USPTO granted patent US12600969B2 to Askbio Inc. on April 14, 2026, covering gene expression regulation using regulatory nucleic acid sequences responsive to the unfolded protein response (UPR). The patent includes 14 claims for regulatable introns and UPR-inducible promoters in recombinant expression constructs. This patent grant does not create compliance obligations.

What changed

The USPTO issued patent US12600969B2 to Askbio Inc. for expression control using a regulatable intron responsive to the unfolded protein response. The patent covers recombinant expression constructs with UPR-inducible promoters and regulatory nucleic acid sequences, with 14 claims granted.

Affected parties including biotech companies, pharmaceutical developers, and investors should monitor this IP for potential licensing opportunities or competitive implications in gene therapy and recombinant protein expression applications.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 15, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Expression control using a regulatable intron

Grant US12600969B2 Kind: B2 Apr 14, 2026

Assignee

Askbio Inc.

Inventors

Graham Whyteside

Abstract

The present invention relates to the use of a regulatory nucleic acid sequences that are able to regulate gene expression in eukaryotic cells and which are responsive to the unfolded protein response (UPR). There are disclosed regulatable introns and UPR-inducible promoters, which are able to regulate gene expression. There are also disclosed recombinant expression constructs comprising such regulatory nucleic acid sequences, whereby expression of the encoded expression product can be induced by invoking the unfolded protein response (UPR) in a eukaryotic cell containing the construct, methods of using such constructs and associated vectors, cells and suchlike.

CPC Classifications

C12N 15/113

Filing Date

2022-11-04

Application No.

17981146

Claims

14

View original document →

Get daily alerts for USPTO Patent Grants - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12600969B2

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254.1 Biotechnology
Activity scope
Patent licensing Biotech research Gene therapy development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Medical Devices Biotechnology

Get alerts for this source

We'll email you when USPTO Patent Grants - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!